Alan G. Zimmermann

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Katherine R. Tuttle, Mark Lakshmanan, Brian Rayner et al. · The Lancet Diabetes & Endocrinology · 2018 · 608 citations

Metabolic Syndrome, Diabetes Management, Renal Function +9

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Francesco Giorgino, Marian Benroubi, Jui‐Hung Sun et al. · Diabetes Care · 2015 · 249 citations · Full text

Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement

Andrea Attanasio, Daojun Mo, Eva Marie Erfurth et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 115 citations · Full text

GH Treatment to Final Height Produces Similar Height Gains in Patients With SHOX Deficiency and Turner Syndrome: Results of a Multicenter Trial

Werner Blum, Judith L. Ross, Alan G. Zimmermann et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 97 citations · Full text

Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients

Mark L. Hartman, Rong Xu, Brenda Crowe et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 87 citations · Full text